0 46

Clinical impact of early recovery of peripheral blood absolute lymphocyte count after frontline autologous stem cell transplantation for diffuse large B-cell lymphoma

Authors
 Yundeok Kim  ;  Soo‐Jeong Kim  ;  June‐Won Cheong  ;  Hyunsoo Cho  ;  Haerim Chung  ;  Jung Yeon Lee  ;  Ji Eun Jang  ;  Yoo Hong Min  ;  Jin Seok Kim 
Citation
 Hematological oncology, Vol.35(4) : 465-471, 2017 
Journal Title
 Hematological oncology 
Issue Date
2017
MeSH
Adult ; Aged ; Disease-Free Survival ; Female ; Hematopoietic Stem Cell Transplantation/methods* ; Humans ; Lymphocyte Count/methods* ; Lymphoma, Large B-Cell, Diffuse/drug therapy* ; Male ; Middle Aged ; Prognosis ; Retrospective Studies ; Transplantation Conditioning/methods* ; Transplantation, Autologous/methods* ; Young Adult
Keywords
absolute lymphocyte count ; diffuse large B-cell lymphoma ; frontline autologous stem cell transplantation ; prognostic marker
Abstract
We conducted a retrospective study to evaluate the clinical impact of an early recovery of posttransplant absolute lymphocyte count (ALC) on the outcome of frontline autologous stem cell transplantation (ASCT) for diffuse large B-cell lymphoma (DLBCL). We reviewed 65 DLBCL patients who underwent frontline ASCT after primary chemotherapy based on cyclophosphamide, doxorubicin, vincristine, and prednisone. A receiver operating characteristic analysis was performed to determine the optimal cut point (0.4 × 109 /L) for an ALC at 15 days after ASCT (ALC-15). Both event-free survival and overall survival rates of the higher-ALC-15 group were significantly better than those of the lower-ALC-15 group (event-free survival, P = .008; overall survival, P = .013). The infused CD34+ cell count was significantly associated with the recovery of ALC-15 (>0.4 × 109 /L) after ASCT (P = .028). A multivariate analysis confirmed that a higher infused CD34+ cell dose (>5.0 × 106 cells/kg) was an independent factor affecting an early recovery of ALC after ASCT (odds ratio, 4.145; 95% confidence interval, 1.106-15.528; P = .035). In conclusion, an early recovery of ALC after ASCT can be regarded as a good prognostic marker in patients with DLBCL who have undergone frontline ASCT. We found that the infused CD34+ cell dose for ASCT was associated with the recovery of ALC.
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/161564
Full Text
https://onlinelibrary.wiley.com/doi/abs/10.1002/hon.2332
DOI
10.1002/hon.2332
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실)
Yonsei Authors
김수정(Kim, Soo Jeong)
김윤덕(Kim, Yun Deok)
김진석(Kim, Jin Seok) ORCID logo https://orcid.org/0000-0001-8986-8436
민유홍(Min, Yoo Hong) ORCID logo https://orcid.org/0000-0001-8542-9583
이정연(Lee, Jung Yoen)
장지은(Jang, Ji Eun) ORCID logo https://orcid.org/0000-0001-8832-1412
정준원(Cheong, June-Won) ORCID logo https://orcid.org/0000-0002-1744-0921
정해림(Chung, Hae Rim) ORCID logo https://orcid.org/0000-0002-7926-9285
Export
RIS (EndNote)
XLS (Excel)
XML
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse